Advertisement

Topics

Indivior increases provisions for litigation matters, but 2017 revenue, profit both rise

06:08 EST 15 Feb 2018 | Proactive Investors

The FTSE 250-listed firm, which last week filed another lawsuit against several generic drugs makers, reported higher revenue and profit for 2017 and said it expects both to rise further in 2018

Original Article: Indivior increases provisions for litigation matters, but 2017 revenue, profit both rise

NEXT ARTICLE

More From BioPortfolio on "Indivior increases provisions for litigation matters, but 2017 revenue, profit both rise"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...